Navigation Links
Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
Date:12/8/2010

SAN DIEGO, Dec. 8, 2010 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The addition of this mutational analysis services agreement broadens Bayer's oncology-focused molecular and pathway activation profiling collaboration with Prometheus to include comprehensive mutational analyses.  The expanded information derived from this agreement has the potential to improve patient stratification in clinical studies and accelerate the development of novel oncology diagnostic and therapeutic products.

Under the terms of this agreement, Bayer will provide clinical samples, sourced from clinical studies, and Prometheus will perform mutational analyses that characterize the presence or absence of existing and novel cancer-relevant mutations in these samples. Prometheus will be compensated based on the number and complexity of mutational analyses it completes for Bayer.

"This agreement represents further validation of the importance of our oncology focused CEER and mutational analysis platforms," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "The combination of our mutational analysis and CEER platforms that this agreement represents is an important step to providing a more comprehensive analysis to Bayer, that may result in improved selection of patients who will benefit the most from specific drug candidates Bayer is developing. We believe this collaboration has the potential to ultimately result in improved outcomes for patients."

Prometheus and Bayer entered into a research collaboration and license agreement in March of this year. This collaboration partners Prometheus' proprietary oncology diagnostic CEER platform with Bayer's broad oncology pipeline with the objective of stratifying patients to
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
8. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
9. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
10. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
11. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
(Date:7/30/2015)... , July 30, 2015   Gaumard® Scientific ... to UNI®, the world,s first operating system to ... now available exclusively to Gaumard users. UNI® version ... launched Newborn Tory™ S2200, as well as improvements ... of clinical measures such as EtCO 2 .  ...
(Date:7/30/2015)... VIEJO, Calif. , July 30, 2015 /PRNewswire/ ... aspiring to eliminate all preventable hospitalization, recently received ... that its Remote Patient Intelligence (RPI) solution meets ... the FDA intends to exercise "Enforcement Discretion." ... "are not subject to further FDA regulatory requirements ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work with ... potential of related, experimental treatments. The collaboration moves into the next phase with the ... one of five state licenses to produce and dispense medical marijuana. , Mount ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB ... of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant ... spontaneous migration of their Implanon® implants, inability to locate the implants, unsuccessful and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida ... novel catheter that was developed for targeted delivery of fluids to selected sites ... treated at Florida Hospital Tampa with the device that provides direct, local delivery ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been developed. Experienced weight loss physicians have raised the HCG diet caloric daily allowance from ... diet protocol written 50 years ago. The physician’s goal with this new HCG diet protocol ... patients. , ...
... ... place on May 6, 2010. Two years in the planning and development, the cutting-edge ... nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott Vein Specialties ...
... with chronic kidney disease have more severe anemia than white ... a multicenter study led by Johns Hopkins Children,s Center to ... Journal of Kidney Disease . The findings suggest that ... may be at play, raising the question whether current guidelines ...
... studies finds that patients, research participants and journal readers ... disclosed, in part because those financial ties may influence ... the April 26 issue of Archives of Internal ... ties to the pharmaceutical, biotechnology and medical device industries ...
... ─ Tiny, melanin-covered nanoparticles may protect bone marrow from ... at Albert Einstein College of Medicine of Yeshiva University ... these particles into human patients may hold promise in ... issue of the International Journal of Radiation Oncology, ...
... are most likely to be good candidates upon death, ... U.S. researchers have developed a new tool that may ... donors, a development that could potentially boost organ donation ... often good candidates for organ donation when they die ...
Cached Medicine News:Health News:Breakthrough in HCG Weight Loss Therapy 2Health News:Breakthrough in HCG Weight Loss Therapy 3Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2Health News:Anemia tougher to tackle in black children with kidney disease 2Health News:Patients, clinicians favor disclosure of financial ties to industry 2Health News:Patients, clinicians favor disclosure of financial ties to industry 3Health News:Novel nanoparticles prevent radiation damage 2Health News:Novel nanoparticles prevent radiation damage 3Health News:Novel nanoparticles prevent radiation damage 4Health News:Test Spots Potential Organ Donors Among Coma Patients 2
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: